NASDAQ:APLT Applied Therapeutics Q3 2025 Earnings Report $0.10 0.00 (0.00%) As of 10/2/2026 ProfileEarnings HistoryForecast Applied Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.15Beat/MissBeat by +$0.02One Year Ago EPSN/AApplied Therapeutics Revenue ResultsActual Revenue$1.00 millionExpected Revenue$0.25 millionBeat/MissBeat by +$750.00 thousandYoY Revenue GrowthN/AApplied Therapeutics Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Applied Therapeutics Earnings HeadlinesExicure (NASDAQ:XCUR) & Applied Therapeutics (NASDAQ:APLT) Financial AnalysisSeptember 28, 2026 | americanbankingnews.comApplied Therapeutics Stock Short Interest Report | NASDAQ:APLT | BenzingaJuly 12, 2026 | benzinga.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Cycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsFebruary 3, 2026 | businesswire.comCycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 30, 2026 | businesswire.comApplied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration ExtensionJanuary 29, 2026 | globenewswire.comSee More Applied Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email. Email Address About Applied TherapeuticsApplied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and other conditions with limited therapeutic options. The company uses its expertise in carbohydrate metabolism and small-molecule drug development to pursue therapies for diseases affecting the nervous system and other organs. Its lead investigational product is govorestat, also known as AT-007, an aldose reductase inhibitor being developed for classic galactosemia, a rare inherited metabolic disorder. Applied Therapeutics has also evaluated govorestat and other pipeline candidates in additional rare neurologic and metabolic conditions. These products remain subject to clinical and regulatory review, and the company does not currently have a broad commercial product portfolio. Applied Therapeutics was founded in 2016 and is headquartered in New York. The company’s research and clinical-development programs have involved collaborations and studies spanning multiple geographic regions. Shoshana Shendelman, Ph.D., is the company’s founder and chief executive officer.View Applied Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
